非小细胞肺癌（NSCLC）是全球癌症相关死亡的主要原因。三级淋巴结构（TLS）是在非生理、非淋巴组织中获得的免疫细胞的有组织的集合。肿瘤组织中 TLS 的高表达通常与更好的预后相关。本研究旨在探讨 TLS 对 NSCLC 患者的预后和临床病理学意义。基于 Pubmed、EMBASE 和 Cochrane Library 数据库进行了全面的文献检索，以确定截至 2023 年 12 月 8 日发表的符合条件的研究。通过计算组合风险比 (HR) 和比值比 (OR) 及其 95% 置信区间 (CI) 来评估 TLS 在 NSCLC 中的价值。随后，进行了额外的分析，包括亚组分析和敏感性分析。这项荟萃分析在涉及 1,451 名 NSCLC 患者的 10 项研究中评估了 TLS 的预后和临床病理学意义。结果显示，高水平的 TLS 与更好的总生存期 (OS)（HR = 0.48，95% CI：0.35-0.66，p< 0.001）、无病生存期 (DFS)/无复发生存期密切相关（ NSCLC 患者中的 RFS）（HR = 0.37，95% CI：0.24-0.54，p < 0.001）和疾病特异性生存（DSS）（HR = 0.45，95% CI：0.30-0.68，p< 0.001）。此外，TLS表达增加与肿瘤的肿瘤淋巴结转移（TNM）分期（OR = 0.71，95% CI：0.51-1.00，p < 0.05）和中性粒细胞-淋巴细胞比值（NLR）（OR = 0.33, 95% CI: 0.17-0.62, p< 0.001）。结果显示，高表达的 TLS 与 NSCLC 患者较好的预后密切相关。 TLS 可以作为一种新型生物标志物来预测 NSCLC 患者的预后并指导临床治疗决策。© 2024。作者。

Non-small cell lung cancer (NSCLC) is the primary reason for cancer-related deaths globally. Tertiary lymphoid structure (TLS) is an organized collection of immune cells acquired in non-physiological, non-lymphoid tissues. High expression of TLS in tumor tissues is generally associated with better prognosis. This research aimed to investigate the prognostic and clinicopathological significance of TLS in patients with NSCLC.A comprehensive literature search was conducted based on Pubmed, EMBASE, and Cochrane Library databases to identify eligible studies published up to December 8, 2023. The prognostic significance and clinicopathological value of TLS in NSCLC were evaluated by calculating the combined hazard ratios (HRs) and odds ratios (ORs) and their 95% confidence intervals (CIs). Following that, additional analyses, including subgroup analysis and sensitivity analysis, were conducted.This meta-analysis evaluated the prognostic and clinicopathological significance of TLS in 10 studies involving 1,451 patients with NSCLC. The results revealed that the high levels of TLS were strongly associated with better overall survival (OS) (HR = 0.48, 95% CI: 0.35-0.66, p < 0.001), disease-free survival (DFS)/recurrence-free survival (RFS) (HR = 0.37, 95% CI: 0.24-0.54, p < 0.001), and disease-specific survival (DSS) (HR = 0.45, 95% CI: 0.30-0.68, p < 0.001) in NSCLC patients. In addition, the increased expression of TLS was closely related to the Tumor Node Metastasis (TNM) stage of tumors (OR = 0.71, 95% CI: 0.51-1.00, p < 0.05) and neutrophil-lymphocyte ratio (NLR) (OR = 0.33, 95% CI: 0.17-0.62, p < 0.001).The results revealed that highly expressed TLS is closely associated with a better prognosis in NSCLC patients. TLS may serve as a novel biomarker to predict the prognosis of NSCLC patients and guide the clinical treatment decisions.© 2024. The Author(s).